General Information of Drug (ID: DM26I8H)

Drug Name
TK-DLI Drug Info
Synonyms
TBI-0301; Herpes simplex thymidine kinase suicide gene therapy, MolMed/Takara Bio; HSV thymidine kinase gene therapy (GvH, retroviral vector), Istituto Scientifico H San Raffaele; HSV-TK suicide gene therapy, MolMed/Takara Bio; TK cell therapy (haploidentical haematopoietic stem cell transplantation), MolMed/Takara Bio; HSV-TK gene therapy (haematological malignancies), MolMed/Takara Bio; TK-DLI, San Raffaele/MolMed/Takara Bio; TK gene/cell therapy (bone marrow transplantation-associated GvHD prevention), MolMed/Takara Bio; TK-expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed; Thymidine kinase expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed/Takara
Indication
Disease Entry ICD 11 Status REF
Graft-versus-host disease 4B24 Preregistration [1]
Cross-matching ID
TTD Drug ID
DM26I8H

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Thymidine kinase 1 (TK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Penciclovir DMOUMDV Human immunodeficiency virus infection 1C62 Approved [3]
DEOXYCYTIDINE DMYE5LJ Acute myeloid leukaemia 2A60 Approved [4]
FV-100 DMZARP1 Varicella zoster virus infection 1E91 Phase 3 [5]
Radiosensitizer gene therapy DMN1ZEU Pancreatic cancer 2C10 Phase 3 [6]
RP101 DMNIYSZ Infectious disease 1A00-CA43.1 Phase 2/3 [7]
HQK-1004 DM3WX0K Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
Rilapladib DMB9861 Arteriosclerosis BD40 Phase 1 [9]
Ad-OC-hsvTK/valacyclovir DM9GLHO Prostate cancer 2C82.0 Phase 1 [10]
Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy DMO8SGD Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
Sitimagene ceradenovec DM0T2QV Brain cancer 2A00 Discontinued in Phase 3 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Thymidine kinase 1 (TK1) TTP3QRF KITH_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023073)
2 Company report (Takara Bio)
3 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4 Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9.
5 Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol. 2002 Feb;61(2):249-54.
6 Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res. 1997 Nov;3(11):2081-8.
7 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
8 Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001 Sep;13(5):360-7.
9 Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1):15-22.
10 Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003 Feb 10;14(3):227-41.
11 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
12 Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. Future Oncol. 2010 Nov;6(11):1691-710.